

**Supplemental material 2 – Reasons for excluding clinical practice guideline (CPG)**

Reference of the excluded CPG	Reasons for exclusion
1. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. Bloomington, MN: ICSI, 2016.	Duplicate
2. Grinspun, D, Bajnok I, Rey M. Delirium, Dementia, and Depression in Older Adults: Assessment and Care. Toronto, Canada: Registered Nurses' Association of Ontario, 2016.	Duplicate
3. Boltz M (Ed.). Evidence-based Geriatric Nursing Protocols for Best Practice. New York, NY: Springer, 2012.	Duplicate
4. MICHIGAN MEDICINE. Ambulatory unipolar depression guideline. [Ann Arbor]: UM; 2021. Available from: <a href="https://michmed-public.policystat.com/policy/8093108/latest/">https://michmed-public.policystat.com/policy/8093108/latest/</a> .	Duplicate
5. Álvarez Ariza M, Atienza Merino G, Ávila González MJ, <i>et al</i> . GPC sobre el Manejo de la Depresión en el Adulto. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2014.	Duplicate
6. National Guideline Clearinghouse. Depression (Singapore). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), 2012. Available from: <a href="https://www.guideline.gov/summaries/summary/39324">https://www.guideline.gov/summaries/summary/39324</a> .	Duplicate
7. Management of Major Depressive Disorder Working Group. VA/DoD clinical practice guideline for the management of major depressive disorder. 3rd ed. Washington, DC: US Department of Veterans Affairs, US Department of Defense, 2016.	Duplicate
8. Austin M-P, Hight N, The Expert Working Group. Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline. Melbourne, Australia: Centre of Perinatal Excellence, 2017.	Focused on specific populations
9. McDermott B, Baigent M, Chanen A, <i>et al</i> . Clinical Practice Guidelines: Depression in Adolescents and Young Adults. Melbourne, Australia: Agency for Healthcare Research and Quality, 2010.	Focused on specific populations
10. Michigan Quality Improvement Consortium Guideline. Primary Care Diagnosis and Management of Adults with Depression. Detroit, MI: MQIC; 2018. Available from: <a href="http://mqic.org/guidelines.htm">http://mqic.org/guidelines.htm</a> .	Duplicate
11. National Institute for Health and Clinical Excellence. Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. Leicester, UK: British Psychological Society, 2005.	Focused on specific populations
12. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. <i>Drugs</i> 2011, 71(1):43-64. DOI:10.2165/11587620-000000000-00000.	Duplicate
13. Kennedy SH, Lam RW, McIntyre RS, <i>et al</i> . Canadian network for mood and anxiety treatments (CANMAT), 2016, clinical CPGs for the management of adults with major depressive disorder: section 3: pharmacological treatments. <i>Can J Psychiatry</i> . 2016, 61(9)540-560. DOI: <a href="https://doi.org/10.1177/0706743716659417">10.1177/0706743716659417</a> .	Duplicate

Reference of the excluded CPG	Reasons for exclusion
14. Taylor RW, Marwood L, Oprea E, <i>et al.</i> Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. <i>Int J Neuropsychopharmacol.</i> 2020, 23(9):587-625. DOI:10.1093/ijnp/pyaa033.	Duplicate
15. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. <i>Journal of Clinical Psychopharmacology and Therapeutics</i> . 2020,16:221-234. Published 2020 Jan 21. DOI: 10.2147/NDT.S198774.	Duplicate
16. Samochowiec J, Dudek D, Kucharska Mazur J, Murawiec S, Rymaszewska J, Cubała WJ, Heitzman J, Szulc A, Bała M, Gątecki P. Pharmacological treatment of a depressive episode and recurrent depressive disorder - guidelines of the Polish Psychiatric Association and the National Consultant for Adult Psychiatry. <i>Psychiatr Pol.</i> 2021 Mar 12;55(2):235-259. English, Polish. DOI: 10.12740/PP/ OnlineFirst/132496. Epub 2021 Mar 12. PMID: 34365477.	Duplicate
17. MICHIGAN MEDICINE. Ambulatory unipolar depression guideline. [Ann Arbor]: UM; 2021. Available from: <a href="https://michmed-public.policystat.com/policy/8093108/latest/">https://michmed-public.policystat.com/policy/8093108/latest/..</a>	Duplicate
18. MALAYSIAN HEALTH TECHNOLOGY ASSESSMENT SECTION. Management of major depressive disorder. 2nd ed. Putrajaya: MaHTAS, 2019. Available from: <a href="http://www.psychiatry-malaysia.org/">http://www.psychiatry-malaysia.org/...</a>	Duplicate
19. Malhi GS, Bell E, Boyce P, Bassett D, Berk M, Bryant R, Gitlin M, Hamilton A, Hazell P, Hopwood M, Lyndon B, McIntyre RS, Morris G, Mulder R, Porter R, Singh AB, Yatham LN, Young A, Murray G. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disord.</i> 2020 Dec, 22(8):805-821. DOI: 10.1111/bdi.13036. PMID: 33296123.	Subject matter
20. Moeller SB, Gbyl K, Hjorthøj C, Andreasen M, Austin SF, Buchholtz PE, Fønss L, Hjerrild S, Hogervorst L, Jørgensen MB, Ladegaard N, Martiny K, Meile J, Packness A, Sigaard KR, Straarup K, Straszek SPV, Soerensen CH, Welcher B, Videbech P. Treatment of difficult-to-treat depression - clinical guideline for selected interventions. <i>Nord J Psychiatry.</i> 2022 Apr, 76(3):177-188. DOI: 10.1080/08039488.2021.1952303. Epub 2021 Aug 28. PMID: 34455900.	Duplicate
21. Kennedy SH, Lam RW, McIntyre RS, <i>et al.</i> Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. <i>Can J Psychiatry</i> 2016, 61:540-60.	Duplicate
22. National Institute for Health and Care Excellence. Depression in Adults: Recognition and Management. 2009. Available from: <a href="https://www.nice.org.uk/guidance/cg90/evidence">https://www.nice.org.uk/guidance/cg90/evidence</a> .	Duplicate

	<b>Reasons for exclusion</b>
23. Ministerio de Salud (CL). Depresión em personas de 15 años y más. Santiago: Minsal, 2013.	Duplicate
24. Ministerio de Salud (COL). Detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos: atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente: Guía de práctica clínica. Bogotá: Minsalud; 2013 [cited 2017 Jun 30]. Available from: <a href="http://www.iets.org.co/reportes-iets/Documentacin%20Reportes/Gu%C3%ADa.Completa.Depresion,2013.pdf">http://www.iets.org.co/reportes-iets/Documentacin%20Reportes/Gu%C3%ADa.Completa.Depresion,2013.pdf</a>	Duplicate
25. Álvarez Ariza M, Atienza Merino G, Ávila González MJ, <i>et al.</i> GPC sobre el Manejo de la Depresión en el Adulto. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2014.	Duplicate
26. National Guideline Clearinghouse. Depression (Singapore). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2012. Available from: <a href="https://www.guideline.gov/summaries/summary/39324..">https://www.guideline.gov/summaries/summary/39324..</a>	Duplicate
27. American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. Retrieved from <a href="https://www.apa.org/depression-guideline">https://www.apa.org/depression-guideline</a> .	Duplicate
28. Bennabi D, Charpeaud T, Yroni A, Genty JB, Destouches S, Lancrenon S, Alaïli N, Bellivier F, Bougerol T, Camus V, Dorey JM, Doumy O, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Llorca PM, Courtet P, Aouizerate B, Haffen E. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the foundation FondaMental. <i>BMC Psychiatry</i> . 2019 Aug 28, 19(1):262. DOI: 10.1186/s12888-019-2237-x. PMID: 31455302, PMCID: PMC6712810.	Duplicate
29. Bennabi D, Yroni A, Charpeaud T, Genty JB, Destouches S, Lancrenon S, Allaili N, Bellivier F, Bougerol T, Camus V, Doumy O, Dorey JM, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Aouizerate B, Haffen E, Llorca PM, Courtet P. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the foundation FondaMental). <i>BMC Psychiatry</i> . 2019 Jan 30, 19(1):50. DOI: 10.1186/s12888-019-2025-7. PMID: 30700272, PMCID: PMC6354367.	Duplicate
30. Malhi, G. S. <i>et al.</i> Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. <i>Medical Journal of Australia</i> , Sydney, v. 208, n. 5, 2018. DOI <a href="http://doi.org/10.5694/mja17.00659">http://doi.org/10.5694/mja17.00659</a> . Available from: <a href="https://www.mja.com.au/journal/2018/208/4/royal-australian-and-new-zealand-college-psychiatrists-clinical-practice">https://www.mja.com.au/journal/2018/208/4/royal-australian-and-new-zealand-college-psychiatrists-clinical-practice</a> .	Duplicate

Reference of the excluded CPG	Reasons for exclusion
31. Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians, 2016. <a href="https://www.acpjournals.org/doi/10.7326/M15-2570">https://www.acpjournals.org/doi/10.7326/M15-2570</a> .	Duplicate
32. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psycho. Available from: <a href="https://www.bap.org.uk/pdfs/BAP_Guidelines-Antidepressants.pdf">https://www.bap.org.uk/pdfs/BAP_Guidelines-Antidepressants.pdf</a> . pharmacologyguidelines. Journal of Psychopharmacology, 2015, v. 29(5) 459-525 DOI: 10.1177/0269881115581093 <a href="http://jop.sagepub.com">jop.sagepub.com</a> .	Duplicate
33. National Institute for Health and Care Excellence. Common Mental Health Disorders. Identification and Pathways to Care. London, UK: NICE, 2011.	Did not include pharmacological treatment
34. Patten SB. Updated CANMAT guidelines for treatment of major depressive disorder. Can J Psychiatry 2016, 61(9):504-5. DOI:10.1177/0706743716660034.	Did not include pharmacological treatment
35. Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 2019, 53(2):109-18. DOI:10.1177/0004867418808585.	Did not include pharmacological treatment
36. Repetitive transcranial magnetic stimulation for depression NICE, 2015. Available from: <a href="https://www.nice.org.uk/guidance/ipg542/resources/repetitive-transcranial-magnetic-stimulation-for-depression-pdf-1899871923433669">https://www.nice.org.uk/guidance/ipg542/resources/repetitive-transcranial-magnetic-stimulation-for-depression-pdf-1899871923433669</a> .	Did not include pharmacological treatment
37. Bennabi D, Haffen E. Transcranial Direct Current Stimulation (tDC): A Promising Treatment for Major Depressive Disorder? Brain Sci. 2018, 8(5):81. Published 2018 May 6. DOI:10.3390/brainsci8050081.	Did not include pharmacological treatment
38. Thompson W, Adcock L. Intensive Day Treatment Programs for Mental Health Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Sep 15. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK513364/">https://www.ncbi.nlm.nih.gov/books/NBK513364/</a> .	Did not include pharmacological treatment
39. Ho C, Adcock L. Short-Term Psychodynamic Psychotherapy for the Treatment of Mental Illness: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Oct 12. PMID: 30234931.	Did not include pharmacological treatment
40. Palylyk-Colwell E, Argáez C. Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018 Apr 10. Disponible en: <a href="https://www.ncbi.nlm.nih.gov/books/NBK532701/">https://www.ncbi.nlm.nih.gov/books/NBK532701/</a> .	Did not include pharmacological treatment
41. Pohar R, Farrah K. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019 Jun 28. PMID: 31433608.	Did not include pharmacological treatment

Reference of the excluded CPG	Reasons for exclusion
42. Ho C, Severn M. e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018 May 16. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK532214/">https://www.ncbi.nlm.nih.gov/books/NBK532214/</a> .	Did not include pharmacological treatment
43. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Internet-delivered cognitive behavioural therapy for major depressive disorder and anxiety disorders. [Ottawa, ON]: CADTH, 2019. Available from: <a href="https://www.cadth.ca/brief-internet-delivered-cognitive-behavioural-therapy-major-depressive-disorder-and-anxiety">https://www.cadth.ca/brief-internet-delivered-cognitive-behavioural-therapy-major-depressive-disorder-and-anxiety</a> .	Did not include pharmacological treatment
44. Frye MA. Clinical practice: bipolar disorder--a focus on depression. N Engl J Med 2011, 364(1):51-9.	Subject matter
45. Andersen BL, DeRubeis RJ, Berman BS, <i>et al</i> . Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014, 32(15):1605-19. DOI:10.1200/JCO.2013.52.4611.	Focused on specific populations
46. American Medical Directors Association. Guideline Summary: Depression in the Long Term Care Setting. Columbia, MD: AMDA; 2011.	Subject matter
47. Li M, Kennedy EB, Byrne N, <i>et al</i> . The management of depression in patients with cancer: a clinical practice guide. J OncolPract 2016, 12(8):747-56. DOI:10.1200/JOP.2016.011072.	Subject matter
48. Ostacher MJ, Tandon R, Suppes T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry 2016, 77(7):920-6. DOI:10.4088/JCP.15cs.09841. Available from: <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L611538719">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L611538719</a>	Subject matter
49. Pfennig A, Bschor T, Falkai P, <i>et al</i> . The diagnosis and treatment of bipolar disorder: recommendations from the current S3 guideline. Dtsch Arztebl Int 110(6):92-100. DOI:10.3238/arztebl.2013.0092. 2013.	Subject matter
50. Rosenblat JD, McIntyre RS. Treatment recommendations for DSM-5-defined mixed features. CNS Spectr 2017, 22(2):147- 54. DOI:10.1017/S1092852916000432.	Subject matter
51. HEALTHCARE IMPROVEMENT SCOTTLAD. Scottish palliative care guidelines: depression. Edinburgh: NHSScotland, 2019. Available from: <a href="https://www.palliativecareguidelines.scot.nhs.uk/guidelines/symptom-control/Depression.aspx">https://www.palliativecareguidelines.scot.nhs.uk/guidelines/symptom-control/Depression.aspx</a> .	Subject matter
52. Assessment and Interventions for Perinatal Depression. Available from: <a href="https://rnao.ca/sites/rnao-ca/files/bpg/Perinatal_Depression_FINAL_web_0.pdf">https://rnao.ca/sites/rnao-ca/files/bpg/Perinatal_Depression_FINAL_web_0.pdf</a> Registered Nurses' Association of Ontario. Assessment and Interventions for Perinatal Depression <sup>ion</sup> . 2nd ed. Toronto (ON): Registered Nurses' Association of Ontario, 2018.	Focused on specific populations

Reference of the excluded CPG	Reasons for exclusion
53. Carneiro LF, Mota MP, Schuch F, Deslandes A, Vasconcelos-Raposo J. Portuguese and Brazilian guidelines for the treatment of depression: exercise as medicine. <i>Braz J Psychiatry</i> . 2017 Aug 30, 40(2):210-211. DOI: 10.1590/1516-4446-2017-2272. PMID: 28876380; PMCID: PMC6900767.	Did not include pharmacological treatment
54. JOBST, A. European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. <i>European Psychiatry</i> , v. 33, n. 2016, p. 18-36. DOI <a href="http://doi.org/10.1016/j.eurpsy.2015.12.003">http://doi.org/10.1016/j.eurpsy.2015.12.003</a> . Available from: <a href="http://www.europsy.net/app/uploads/2016/05/Psychotherapy-in-chronic-depression-across-Europe.pdf">http://www.europsy.net/app/uploads/2016/05/Psychotherapy-in-chronic-depression-across-Europe.pdf</a> .	Did not include pharmacological treatment
55. FSRH CEU Statement: Response to published study: Association of Hormonal Contraception with Depression (October 2016) <a href="file:///C:/Users/Usuario/Downloads/association-of-hc-with-depression%20(1).pdf">file:///C:/Users/Usuario/Downloads/association-of-hc-with-depression%20(1).pdf</a> .	Was not a CPG
56. Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration: An Updated Report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional Anesthesia and Pain Medicine*. <i>Anesthesiology</i> 2016, 124:535–552 DOI: <a href="https://doi.org/10.1097/ALN.0000000000000975">https://doi.org/10.1097/ALN.0000000000000975</a> .	Subject matter
57. Manipulating the sleep-wake cycle and circadian rhythms to improve clinical management of major depression DOI:10.1186/1741-7015-11-79. <i>BMC Medicine</i> 2013, 11:79.	Subject matter
58. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Space from depression for treating adults with depression. [London]: NICE, 2020. Available from: <a href="https://www.nice.org.uk/advice/mib215/resources/space-from-depression-for-treating-adults-with-depression-pdf-2285965453227973">https://www.nice.org.uk/advice/mib215/resources/space-from-depression-for-treating-adults-with-depression-pdf-2285965453227973</a> .	Subject matter
59. Goracci A, Forgione RN, De Giorgi R, Coluccia A, Cuomo S, Fagiolini A. Practical guidance for prescribing trazodone extended-release in major depression. <i>Expert Opin Pharmacother</i> . 2016, 17(3):433-41. DOI:	Specific drugs
60. Kandasamy S, Campbell K. Psychotherapy and Pharmacotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Rapid Qualitative Review [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019 Jun 4. PMID: 33074608.	Was not a CPG
61. Antidepressants in Elderly Patients with Major and Minor Depression: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2015 Aug 17. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK315889/">https://www.ncbi.nlm.nih.gov/books/NBK315889/</a> .	Was not a CPG

Reference of the excluded CPG	Reasons for exclusion
62. WELLS, C., CAMPBELL, K. Antidepressants for adults with depression using opioid medications: clinical effectiveness and guidelines. Ottawa, ON: CADTH, 2018 Feb. (CADTH rapid response report: summary of abstracts).	Was not a CPG
63. Kim J, Mierzwinski-Urban M. Ketamine for Treatment-Resistant Depression or Post-Traumatic Stress Disorder in Various Settings: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Mar 1. PMID: 29533569.	Focused on specific populations
64. TADROUS, M., LÉSÉLEUC, L. Drugs for major depressive disorder. Ottawa, ON: CADTH, 2020 Feb. (CADTH technology review: focused critical appraisal; n. 24). Available from: <a href="https://www.cadth.ca/major-depressive-disorder-focused-critical-appraisal-network-meta-analysis">https://www.cadth.ca/major-depressive-disorder-focused-critical-appraisal-network-meta-analysis</a> .	Was not a CPG
65. Diagnosing, Screening, and Monitoring Depression in the Elderly: A Review of Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2015 Sep 8. PMID: 26468558.	Was not a CPG
66. E-NOTAS. Modelos e intervenciones de colaboración entre atención primaria y salud mental en la atención a los pacientes diagnosticados de depresión: resultados de una meta-revisión. [Oviedo]: 2014. Available from: <a href="https://enotas.astursalud.es/-/modelos-e-intervenciones-de-colaboraci%C3%B3n-entre-atenci%C3%B3n-primaria-y-salud-mental-en-la-atenci%C3%B3n-a-los-pacientes-diagnosticados-de-depresi%C3%B3n-resultados-de-una-meta-revisi%C3%B3n-">https://enotas.astursalud.es/-/modelos-e-intervenciones-de-colaboraci%C3%B3n-entre-atenci%C3%B3n-primaria-y-salud-mental-en-la-atenci%C3%B3n-a-los-pacientes-diagnosticados-de-depresi%C3%B3n-resultados-de-una-meta-revisi%C3%B3n-</a> .	Was not a CPG
67. MacDonald E, Horton J. Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK571946/">https://www.ncbi.nlm.nih.gov/books/NBK571946/</a> .	Was not a CPG
68. Poitras V, Visintini S. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Oct 25. PMID: 29889482.	Was not a CPG
69. YATHAM, L. Cognitive heterogeneity in bd: validity, trajectories and biological mechanisms symposium [Symposium Abstracts; SY1]. Bipolar Disorders, Copenhagen v. 23, n. S1, p. 15-47. DOI <a href="https://doi.org/10.1111/bdi.13086">https://doi.org/10.1111/bdi.13086</a> . Available from: <a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13086">https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13086</a> .	Was not a CPG
70. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Antidepressants administered using weight-based dosing strategies for depression: clinical effectiveness and guidelines. [Ottawa, ON]: CADTH; 2020. Available from: <a href="https://www.cadth.ca/antidepressants-administered-using-weight-based-dosing-strategies-depression-clinical-effectiveness">https://www.cadth.ca/antidepressants-administered-using-weight-based-dosing-strategies-depression-clinical-effectiveness</a> .	Was not a CPG

Reference of the excluded CPG	Reasons for exclusion
71. Li KX, Loshak H. Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019 Oct 24. PMID: 31873996.	Was not a CPG
72. Testosterone for depression, PTSD, or fibromyalgia: Clinical effectiveness and guidelines. Ottawa: CADTH, 2017, Feb. (CADTH rapid response report: reference list).	Was not a CPG
73. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. <b>Monoamine oxidase inhibitors in elderly patients:</b> clinical effectiveness and guidelines. [Ottawa, ON]: CADTH, 2015. Available from: <a href="https://www.cadth.ca/sites/default/files/thisfile/htis/aug-2015/RA0792%20MAOIs%20in%20the%20Elderly%20Final.pdf">https://www.cadth.ca/sites/default/files/thisfile/htis/aug-2015/RA0792%20MAOIs%20in%20the%20Elderly%20Final.pdf</a> .	Was not a CPG
74. Alexopoulos GS. Pharmacotherapy for late-life depression. <i>J Clin Psychiatry</i> 2011, 72(1):e04. DOI:10.4088/JCP.7085tx2cj.	Was not a CPG
75. Andreescu C, Reynolds CF III. Late-life depression: evidencebased treatment and promising new directions for research and clinical practice. <i>Psychiatr Clin North Am</i> 2011, 34(2):335-55. DOI:10.1016/j.psc.2011.02.005.	Was not a CPG
76. Arnow BA, Steidtmann D, Blasey C, <i>et al.</i> The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. <i>J Consult Clin Psychol</i> 2013, 81(4):627-38. DOI:10.1037/a0031530.	Was not a CPG
77. Ayub-Dargél A, Masson M, Henry C. The RANZCP guidelines: managing mood disorders in the real world. <i>Aust N Z J Psychiatry</i> 2016, 50(12): 1198-9. DOI:10.1177/0004867416676373.	Was not a CPG
78. Bland P. Raising standards of care for patients with depression. <i>Practitioner</i> 2011, 255(1740):21-5.	Was not a CPG
79. Boffin N, Bossuyt N, Declercq T, <i>et al.</i> Incidence, patient characteristics and treatment initiated for GP-diagnosed depression in general practice: results of a 1-year nationwide surveillance study. <i>Fam Prac</i> 2012, 29(6):678-87. DOI:10.1093/fampra/cms024.	Was not a CPG
80. Bohra HM, Novak M. Depression in patients with chronic kidney disease. <i>CANNT J</i> 2015, 25(3):34-8.	Was not a CPG
81. Cohen A. The QOF, NICE, and depression. <i>Br J Gen Pract</i> 2011, 61(590):549. DOI:10.3399/bjgp11X593785.	Was not a CPG
82. Baumann S, Benson-Martin J, Cossie Q, <i>et al.</i> SASOP treatment guidelines for psychiatric disorders: eminence or evidence based? <i>S Afr J Psychiatr</i> 2019, 20(2):a529. DOI 10.4102/sajpsychiatry.v20i2.529.	Was not a CPG
83. Cosgrove L, Shaughnessy AF, Wheeler EE, <i>et al.</i> The American Psychiatric Association's guideline for major depressive disorder: a commentary. <i>Psychother Psychosom</i> 2012, 81(3):186-8. DOI:10.1159/000335523.	Was not a CPG



Reference of the excluded CPG	Reasons for exclusion
84. Cuijpers P. Effective therapies or effective mechanisms in treatment guidelines for depression? <i>Depress Anxiety</i> 2013, 30(11):1055-7. DOI:10.1002/da.22205.	Was not a CPG
85. Cuijpers P. Combined pharmacotherapy and psychotherapy in the treatment of mild to moderate major depression? <i>JAMA Psychiatry</i> 2014, 71(7):747-8. DOI:10.1001/jamapsychiatry.2014.277.	Was not a CPG
86. De Coteau PA, Byrne CD, Russell, V. The HSE/ICGP guidelines on the management of depression and anxiety disorders in primary care. <i>Ir Med J</i> 2012, 105(7):251.	Was not a CPG
87. Desseilles M, Witte J, Chang TE, <i>et al.</i> Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. <i>J Clin Psychiatry</i> 2011, 72(8):1152-4. DOI:10.4088/JCP.11ac07225.	Was not a CPG
88. Canadian Agency for Drugs and Technologies in Health. Diagnosing, Screening, and Monitoring Depression in the Elderly: A Review of Guidelines. Ottawa, ON: CADTH, 2015.	Was not a CPG
89. Canadian Agency for Drugs and Technologies in Health. Antidepressants in Elderly Patients with Major and Minor Depression: A Review of Clinical Effectiveness and Guidelines. Ottawa, ON: CADTH, 2015.	Was not a CPG
90. Gensichen J, Härter M, Klesse C, <i>et al.</i> Germany's national clinical practice guideline (S3) for unipolar depression—What is important for family practice? <i>ZFA</i> 2011, 87(5):223-30. DOI:10.3238/zfa.2011.0223.	Was not a CPG
91. GEOFFROY, P. A., BELLIVIER, F. The RANZCP mood disorders guidelines: an easy step-by-step toolbox for daily practice. <i>Australian and New Zealand Journal of Psychiatry</i> , Melbourne, v. 50, n. 10, p. 1014-5. DOI Available from: <a href="https://journals.sagepub.com/doi/10.1177/0004867416667829">https://journals.sagepub.com/doi/10.1177/0004867416667829</a> .	Was not a CPG
92. Gitlin M. The Royal Australian and New Zealand College of Psychiatrists clinical guidelines for mood disorders: kudos and quarrels. <i>Aust NZ Psychiatry</i> 2016, 50(10):937-8. DOI:10.1177/0004867416668038.	Was not a CPG
93. Grobler, G. An overview of depression treatment guidelines. Abstracts 2nd African College of Neuropsychopharmacology Congress 30-31 July 2016 Stellenbosch, Western Cape, South Africa. <i>Acta Neuropsychiatr</i> 2016, 28(s3):1-15. DOI:10.1017/neu.2016.37.	Was not a CPG
94. Heilmann KE, Wagner M, Riedel-Heller S, <i>et al.</i> Treating late life depression with antidepressants: a summary of recommendations in international guidelines. <i>Fortschr Neurol Psychiatr</i> 2015, 83(7):381-91. DOI:10.1055/s-0035-1553315.	Was not a CPG
95. Horgan D, Dodd S. Combination antidepressants—use by GPs and psychiatrists. <i>Aust Fam Physician</i> 2011, 40(6):397-400.	Was not a CPG

Reference of the excluded CPG	Reasons for exclusion
96. KASPER, S. Editorial. World Journal of Biological Psychiatry, Glasgow, v. 14, n. 5, p. 333. DOI <a href="https://doi.org/10.3109/15622975.2013.819703">https://doi.org/ 10.3109/15622975.2013.819703</a> . Available from: <a href="https://www.tandfonline.com/doi/full/10.3109/15622975.2013.819703">https://www.tandfonline.com/doi/full/10.3109/15622975.2013.819703</a> .	Was not a CPG
97. Kendall T, Pilling S, Glover N, <i>et al.</i> Guidelines in ment–l health - national and international perspectives. Int Rev Psychiatry 2011, 23(4):314-7. DOI:10.3109/09540261.2011.607431.	Was not a CPG
98. Kongsuk T. Clinical practice guideline major depressive disorder for general practitioners. Value Health 2013, 16(7): A695. DOI:10.1016/j.jval.2013.08.2091.	Was not a CPG
99. KURIAN, B. T., GRANNEMANN, B., TRIVEDI, M. H. Feasible evidence-based strategies to manage depression in primary care. <b>Current Psychiatry Reports</b> , Philadelphia, v. 14, n. 4, p. 370-375. DOI: <a href="https://doi.org/10.1007/s11920-0120290-y">https://doi.org/10.1007/s11920-0120290-y</a> . Available from: <a href="https://link.springer.com/article/10.1007/s11920-012-0290-y">https://link.springer.com/article/10.1007/s11920-012-0290-y</a> .	Was not a CPG
100. Laux G. Update treatment of depression—S3 Guideline, internet-based psychotherapy, antidepressants and driving ability. Nervenheilkunde 2016, 35(10):691-6. DOI:10.1055/s-0037-1616433.	Was not a CPG
101. FACULTY OF SEXUAL AND REPRODUCTIVE HEALTHCARE OF THE ROYAL COLLEGE OF OBSTETRICIANS AND GYNEACOLOGISTS. The relationship between progestin hormonal contraception and depression: a systematic review. [London]: 6 March 2018. Available from: <a href="https://www.fsrh.org/news/fsrh-ceu-statement-response-to-study-on-progestogen-only/">https://www.fsrh.org/news/fsrh-ceu-statement-response-to-study-on-progestogen-only/</a> .	Was not a CPG
102. FACULTY OF SEXUAL AND REPRODUCTIVE HEALTHCARE OF THE ROYAL COLLEGE OF OBSTETRICIANS AND GYNEACOLOGISTS. FSRH CEU Statement: response to study on progestogen-only contraception use and depression [London]: FSRH; 8 March 2018. Available from: <a href="https://www.fsrh.org/news/fsrh-ceu-statement-response-to-study-on-progestogen-only/">https://www.fsrh.org/news/fsrh-ceu-statement-response-to-study-on-progestogen-only/</a> .	Was not a CPG
103. Leadholm AKK, Rothschild AJ, Nolen WA <i>et al.</i> The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord 145(2): 214-20. DOI:10.1016/j.jad.2012.07.036.	Focused on specific populations
104. Malhi G, Oakley-Browne M, Hay P. Clinical practice guidelines project (CPG project) overview. Aust NZ JPsychiatr 2015, 49(Supp 1):30. DOI:10.1177/0004867415578344.	Was not a CPG
105. Manning JS, Jackson WC. Providing guideline-concordant assessment and monitoring for major depression in primary care. J Clin Psychiatry 2015, 76(1):e3. DOI:10.4088/JCP.13013tx7c.	Was not a CPG
106. Morris DW, Trivedi MH. Measurement-based care for unipolar depression. Curr Psychiatry Rep 2011, 13(6):446-58. DOI:10.1007/s11920-011-0237-8.	Was not a CPG

Reference of the excluded CPG	Reasons for exclusion
107. Nelson JC. Foreword. CNSDrugs 2013, 27:3-4. DOI:10.1007/s40263-012-0027-9.	Was not a CPG
108. Nutt DJ. Highlights of the international consensus statement on major depressive disorder. J Clin Psychiatry 2011, 72(6):e21. DOI:10.4088/JCP.9058tx2c.	Was not a CPG
109. Ogasawara K, Ozaki N. Review of the new treatment guideline for major depressive disorder by the Japanese Society of Mood Disorders. Brain Nerve 2012, 64(10):1159-65. In Japanese.	Was not a CPG
110. Oldham J. Fine-tuning our treatment strategies. J Psychiatr Pract 2011, 17(3):157. DOI:10.1097/01.pra.0000398408.13750.8d.	Was not a CPG
111. Pai N. Are the Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders meeting the needs of clinicians? Aust N Z J Psychiatry 2016, 50(10):1015-6. DOI:10.1177/0004867416667828.	Was not a CPG
112. Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 2013, 27(Suppl 1):S29-S37. DOI:10.1007/s40263-012-0031-0.	Was not a CPG
113. Rawlins M. Ten years of NICE mental health guidelines. Int Rev Psychiatry 2011, 23(4):311-3. DOI:10.3109/09540261.2011.606804.	Was not a CPG
114. Reisdorf S. Revision of the national health care guidelines on unipolar depression. MedMonatss Pharm 2016, 39(4):171-2.	Was not a CPG
115. Roberge P, Fournier L, Brouillet H, <i>et al.</i> A provincial adaptation of clinical practice guidelines for depression in primary care: a case illustration of the ADAPTE method. J Eval Clin Pract 2015, 21(6):1190-8. DOI:10.1111/jep.12404.	Was not a CPG
116. Schuklenk U, Vathorst SVD. Treatment-resistant major depressive disorder and assisted dying. J Med Ethics 2015, 41(8), 577-83. DOI:10.1136/medethics-2014-102458.	Was not a CPG
117. Schulte-Korne G, Krick K. In reply. Dtsch Arztebl Int 2014, 111(18):330. DOI:10.3238/arztebl.2014.0330c.	Was not a CPG
118. Tomba E, Fava GA. Treatment selection in depression: the role of clinical judgment. Psychiatr Clin North Am 2012, 35(1):87-98. DOI:10.1016/j.psc.2011.11.003.	Was not a CPG
119. TREUER, T., <i>et al.</i> Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited. <i>Asia-Pacific Psychiatry</i> , Richmond, v. 5, n. 4, p. 219-230. DOI <a href="https://doi.org/10.1111/appy.12090">https://doi.org/10.1111/appy.12090</a> . Available from: <a href="https://onlinelibrary.wiley.com/doi/10.1111/appy.12090">https://onlinelibrary.wiley.com/doi/10.1111/appy.12090</a> .	Was not a CPG
120. Tundo A, Calabrese JR, Proietti L, <i>et al.</i> Short-term antidepressant treatment of bipolar depression: are ISBD recommendations useful in clinical practice? J Affect Disord 2015, 171:155-60. doi:10.1016/j.jad.2014.09.019.	Focused on specific populations

Reference of the excluded CPG	Reasons for exclusion
121. Van Avendonk M, van Weel-Baumgarten E, van der Weele G, <i>et al.</i> Summary of the Dutch College of General Practitioners' practice guideline "Depression". <i>Ned Tijdschr Geneesk</i> 2012, 156(38):A5101.	Was not a CPG
122. Vinberg M, Levinsen MF, Kessing LV. Treatment-resistant depression is treatable. <i>Ugeskr Laeger</i> 2011, 173(9):651-4.	Was not a CPG
123. Xiang YT, Hu C, Wang G, <i>et al.</i> Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China. <i>Hum Psychopharmacol</i> 2012, 27(6):626-31. DOI:10.1002/hup.2262.	Was not a CPG
124. YANG, J. <i>et al.</i> Experiences and barriers to implementation of clinical practice guideline for depression in Korea. <i>BMC Psychiatry</i> , London, v. 13, p. 150. DOI: <a href="https://doi.org/10.1186/1471-244X-13-150">https://doi.org/10.1186/1471-244X-13-150</a> . Available from: <a href="https://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-150">https://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-150</a> .	Was not a CPG
125. Zimmerman M. Symptom severity and guideline-based treatment recommendations for depressed patients: implications of DSM-5's potential recommendation of the PHQ-9 as the measure of choice for depression severity. <i>Psychother Psychosom</i> 2012, 81(6):329-32. DOI:10.1159/000342262.	Was not a CPG
126. Zimmerman M, Martinez JH, Friedman M, <i>et al.</i> How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? <i>J Clin Psychiatry</i> 2012, 73(10):1287-91. DOI:10.4088/JCP.12m07775.	Was not a CPG
127. Herrmann M, Gensichen J. Guidelines in general practice: the example depression. <i>Psychiatrie</i> 2015, 66:119-24.	Was not a CPG
128. Kuroki T, Tanaka T. [Threshold of application of antidepressant drugs for treatment of depressive disorder]. <i>Seishin Shinkeigaku Zasshi</i> 2015,117(4):269-76. In Japanese.	Was not a CPG
129. Semba J. [Proper use of novel antidepressants in psychiatric clinical practice]. <i>Seishin Shinkeigaku Zasshi</i> . 2014,116(2):138-143. In Japanese.	Was not a CPG
130. Sforzini, L., Worrell, C., Kose, M. <i>et al.</i> A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Mol Psychiatry</i> (2021). <a href="https://doi.org/10.1038/s41380-021-01381-x">https://doi.org/10.1038/s41380-021-01381-x</a> .	Did not include pharmacological treatment
131. McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi GS, Soares JC, Vieta E, Young AH, Papadopoulos A, Rush AJ. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. <i>J Affect Disord</i> . 2020 Apr 15, 267:264-282. DOI: 10.1016/j.jad.2020.02.023. Epub 2020 Feb 7. PMID: 32217227.	Was not a CPG

Reference of the excluded CPG	Reasons for exclusion
132. Lu, S., Li, W., Oldenburg, B. <i>et al.</i> Cultural adaptation of the mental health first aid guidelines for depression used in English-speaking countries for China: a Delphi expert consensus study. <i>BMC Psychiatry</i> 20, <a href="https://doi.org/10.1186/s12888-020-02736-4">336 (2020)</a> . <a href="https://doi.org/10.1186/s12888-020-02736-4">https://doi.org/10.1186/s12888-020-02736-4</a> .	Was not a CPG
133. Taylor RW, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B, Zahn R, Young AH, Cleare AJ. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. <i>Int J Neuropsychopharmacol.</i> 2020 Dec 3, 23(9):587-625. DOI: 10.1093/ijnp/pyaa033. PMID: 32402075; PMCID: PMC7710919.	Was not a CPG
134. Andrade C. Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include. <i>Bipolar Disord.</i> 2022 Mar, 24(2):113-114. DOI: 10.1111/bdi.13155. Epub 2021 Nov 23. PMID: 34816542.	Was not a CPG
135. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Accessing mental health support outside of a therapist's office: iCBT for major depression and anxiety disorders. [Ottawa, ON]: CADTH, [2020]. Available from: <a href="https://www.cadth.ca/events/evidence-action-accessing-mental-health-support-outside-therapists-office-icbt-major">https://www.cadth.ca/events/evidence-action-accessing-mental-health-support-outside-therapists-office-icbt-major</a> .	Subject matter
136. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Common mental health problems: identification and pathways to care. <b>London: NICE, 2011. Available from:</b> <a href="https://www.nice.org.uk/guidance/cg123">https://www.nice.org.uk/guidance/cg123</a> .	Subject matter
137. HAUTE AUTORITÉ DE SANTÉ. Dangersité psychiatrique: étude et évaluation des facteurs de risque de violence hétéro-agressive chez les personnes ayant des troubles schizophréniques ou des troubles de l'humeur. Saint-Denis, 2011. Available from: <a href="https://www.has-sante.fr/jcms/c_1069220/fr/dangerosite-psychiatrique-etude-et-evaluation-des-facteurs-de-risque-de-violence-hetero-agressive-chez-les-personnes-ayant-des-troubles-schizophreniques-ou-des-troubles-de-l-humeur">https://www.has-sante.fr/jcms/c_1069220/fr/dangerosite-psychiatrique-etude-et-evaluation-des-facteurs-de-risque-de-violence-hetero-agressive-chez-les-personnes-ayant-des-troubles-schizophreniques-ou-des-troubles-de-l-humeur</a> .	Subject matter
138. Arbejdsgruppen vedr. den nationale kliniske retningslinje for farmakologisk behandling af bipolar lidelse. National klinisk retningslinje for farmakologisk behandling af bipolar lidelse: supplerende vedligeholdelsesbehandling efter depression. Version 27. maj 2014 udg. København: Sundhedsstyrelsen, 2014. 111 s.	Subject matter
139. Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. <i>J Clin Psychiatry.</i> 2011 Dec, 72(12):e36. DOI: 10.4088/JCP.10027tx4cc. PMID: 22244032.	Was not a CPG
140. Lam RW, Parikh SV, Michalak EE, Dewa CS, Kennedy SH. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. <i>Ann Clin Psychiatry.</i> 2015 May, 27(2):142-9. PMID: 25954941.	Subject matter

Reference of the excluded CPG	Reasons for exclusion
141. Human growth hormone for depression, post-traumatic stress disorder, or fibromyalgia: Clinical effectiveness and guidelines. Ottawa: CADTH, 2017 Feb. (CADTH rapid response report: reference list).	Subject matter
142. Yamada K. [Evidence of treatment for depressive episodes of bipolar disorder]. <i>Seishin Shinkeigaku Zasshi</i> 2011, 113(9):873-9. In Japanese.	Subject matter
143. Depression. Adapted Evidence-based Guideline. Ukraine, 2014.	Was not a CPG
144. Siu AL, US Preventive Services Task Force (USPSTF). Screening for depression in adults: US Preventive Services Task Force recommendation statement. <i>JAMA</i> 2016, 315(4):380-7. DOI:10.1001/jama.2015.18392.	Did not include pharmacological treatment
145. Thase ME. Recommendations for screening for depression in adults. <i>JAMA</i> 2016, 315(4):349-50. DOI:10.1001/jama.2015.18406.	Did not include pharmacological treatment
146. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Internet-Delivered Cognitive Behavioural Therapy (iCBT) programs for major depression and anxiety disorders in Canada. Ottawa, ON: CADTH, 2020. Available from: <a href="https://www.cadth.ca/internet-delivered-cognitive-behavioural-therapy-icbt-programs-major-depression-and-anxiety">https://www.cadth.ca/internet-delivered-cognitive-behavioural-therapy-icbt-programs-major-depression-and-anxiety</a>	Did not include pharmacological treatment
147. Guided Versus Unguided Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Comparative Clinical Effectiveness. Ottawa: CADTH, 2018 Oct. (CADTH rapid response report: summary of abstracts).	Did not include pharmacological treatment
148. Pohar R, Argáez C. Acceptance and Commitment Therapy for Post-Traumatic Stress Disorder, Anxiety, and Depression: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Aug 28. PMID: 30226695.	Did not include pharmacological treatment
149. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Mindfulness interventions for the treatment of post-traumatic stress disorder, generalized anxiety disorder, depression, and substance use disorders: a review of the clinical effectiveness and guidelines. Ottawa, ON: CADTH, 2015. Available from: <a href="https://www.cadth.ca/mindfulness-interventions-treatment-post-traumatic-stress-disorder-generalized-anxiety-disorder">https://www.cadth.ca/mindfulness-interventions-treatment-post-traumatic-stress-disorder-generalized-anxiety-disorder</a> .	Did not include pharmacological treatment
150. Yoga for the Treatment of Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Depression, and Substance Abuse: A Review of the Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2015 Jun 22. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK304560/">https://www.ncbi.nlm.nih.gov/books/NBK304560/</a> .	Did not include pharmacological treatment

Reference of the excluded CPG	Reasons for exclusion
151. Health Quality Ontario. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. <i>Ont Health Technol Assess Ser.</i> 2019- Feb 19, 19(6):1-199. PMID: 30873251; PMCID: PMC6394534.	Did not include pharmacological treatment
152. Bright Light Therapy for Depression: Clinical Effectiveness. Ottawa: CADTH, 2019 Aug. (CADTH rapid response report: summary of abstracts).	Did not include pharmacological treatment
153. Physical activity and support programs for mild to moderate major depressive disorder. (CADTH reference list). Ottawa: CADTH, 2021 November.	Did not include pharmacological treatment
154. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Diagnosing, screening, and monitoring depression in the elderly: a review of guidelines. Ottawa, ON: CADTH, 2015.	Did not include pharmacological treatment
155. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. Stellate ganglion block for the treatment of post-traumatic stress disorder, depression, and anxiety. Ottawa, ON: CADTH, 2021. Available from: <a href="https://www.cadth.ca/stellate-ganglion-block-treatment-post-traumatic-stress-disorder-depression-and-anxiety">https://www.cadth.ca/stellate-ganglion-block-treatment-post-traumatic-stress-disorder-depression-and-anxiety</a> .	Did not include pharmacological treatment
156. Pharmacogenomic testing in depression: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: CADTH, 2020 Jan. (CADTH rapid response report: summary with critical appraisal).	Did not include pharmacological treatment
157. CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH. <b>Repetitive transcranial magnetic stimulation for depression</b> : a review of the clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: CADTH, 2021. Available from: <a href="https://www.cadth.ca/repetitive-transcranial-magnetic-stimulation-depression-review-clinical-effectiveness-cost">https://www.cadth.ca/repetitive-transcranial-magnetic-stimulation-depression-review-clinical-effectiveness-cost</a> .	Did not include pharmacological treatment
158. Health Quality Ontario. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. <i>Ont Health Technol Assess Ser.</i> 2019 Feb 19, 19(6):1-199. PMID: 30873251; PMCID: PMC6394534.	Did not include pharmacological treatment
159. NATIONAL KLINISK RETNINGSLINJE FOR NON-FARMAKOLOGISK BEHANDLING AF UNIPOLAR DEPRESSION. Available from: <a href="https://www.sst.dk/da/udgivelser/2016/~media/0216564bb8aa4d40b7dbaf21e9acf403.ashx">https://www.sst.dk/da/udgivelser/2016/~media/0216564bb8aa4d40b7dbaf21e9acf403.ashx</a> .	Did not include pharmacological treatment
160. Joffres M, Jaramillo A, Dickinson J, <i>et al.</i> Recommendations on screening for depression in adults [published correction appears in <i>CMAJ.</i> 2013 Sep 3, 185(12):1067]. <i>CMAJ.</i> 2013;185(9):775-782. DOI:10.1503/cmaj.130403.	Did not include pharmacological treatment

Reference of the excluded CPG	Reasons for exclusion
161. Andersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., Holland, J. C., Partridge, A. H., Bak, K., Somerfield, M. R., Rowland, J. H., & American Society of Clinical Oncology (2014). Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. <i>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</i> , 32(15), 1605–1619. <a href="https://doi.org/10.1200/JCO.2013.52.4611">https://doi.org/10.1200/JCO.2013.52.4611</a>	Did not include pharmacological treatment
162. Implanted vagus nerve stimulation for treatment-resistant depression. Available from: <a href="https://www.nice.org.uk/guidance/ipg679">https://www.nice.org.uk/guidance/ipg679</a> .	Did not include pharmacological treatment
163. FROST, J. <i>et al.</i> Depression following acute coronary syndrome events: screening and treatment guidelines from the AAFP. <i>American Family Physician</i> , Kansas City, MO, v. 99, n. 12, online. Available from: <a href="https://www.aafp.org/afp/2019/0615/od2.html">https://www.aafp.org/afp/2019/0615/od2.html</a> .	Focused on specific populations
164. Noe KH, Locke DE, Sirven JI. Treatment of depression in patients with epilepsy. <i>Curr Treat Options Neurol</i> . 2011 Aug;13(4):371-9. DOI: 10.1007/s11940-011-0127-8. PMID: 21472437.	Focused on specific populations
165. Rayner L, Price A, Hotopf M, <i>et al.</i> The development of evidence-based European guidelines on the management of depression in palliative cancer care. <i>Eur J Cancer</i> 2011, 47(5):702-12. DOI:10.1016/j.ejca.2010.11.027.	Focused on specific populations
166. Williams D, Mierzwinski-Urban M. Adapted or Tailored Psychological Interventions for Treating Women with Mental Illness: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017 Oct 5. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK525628/">https://www.ncbi.nlm.nih.gov/books/NBK525628/</a> .	Focused on specific populations
167. WORLD HEALTH ORGANIZATION. <b>Pharmacological interventions (antidepressants) for 433 people with dementia who have associated depression</b> . Geneva: WHO, 2015. Available from: <a href="https://www.who.int/mental_health/mhgap/evidence/emmentia/q4/en/">https://www.who.int/mental_health/mhgap/evidence/emmentia/q4/en/</a> .	Focused on specific populations
168. Austin M-P, Hight N, The Expert Working Group. <i>Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline</i> . Melbourne, Australia: Centre of Perinatal Excellence, 2017.	Focused on specific populations
169. Colquhoun DM, Bunker SJ, Clarke DM, <i>et al.</i> Screening, referral and treatment for depression in patients with coronary heart disease. <i>Med J Aust</i> 2013, 198(9):483-4. DOI:10.5694/mja13.10153.	Focused on specific populations
170. Perinatal Depression Screening, Diagnosis, and treatment Guideline. Available from: <a href="https://wa.kaiserpermanente.org/static/pdf/public/guidelines/depression-perinatal.pdf">https://wa.kaiserpermanente.org/static/pdf/public/guidelines/depression-perinatal.pdf</a> .	Focused on specific populations



Reference of the excluded CPG	Reasons for exclusion
171. Andersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., Holland, J. C., Partridge, A. H., Bak, K., Somerfield, M. R., Rowland, J. H., & American Society of Clinical Oncology (2014). Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. <i>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</i> , 32(15), 1605–1619. <a href="https://doi.org/10.1200/JCO.2013.52.4611">https://doi.org/10.1200/JCO.2013.52.4611</a> .	Focused on specific populations
172. Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, Sellick S, Green E. Management of Depression in Patients With Cancer: A Clinical Practice Guideline. <i>J Oncol Pract</i> . 2016 Aug. 12, (8):747-56. DOI: 10.1200/JOP.2016.011072. Epub 2016 Jul 5. Erratum in: <i>J Oncol Pract</i> . 2017 Feb;13(2):144. PMID: 27382000.	Focused on specific populations
173. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Depression in adults with a chronic physical health problem: recognition and management. London: NICE, 2009. Available from: <a href="https://www.nice.org.uk/guidance/cg91">https://www.nice.org.uk/guidance/cg91</a> .	Focused on specific populations
174. MINISTERIO DE SALUD. Guía Clínica: Abordaje de la depresión en mujeres con cáncer de mama. Santiago: Minsal, 2017. Available from: <a href="https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2017/07/GPC_depresion_en_cancer_de_mama.pdf">https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2017/07/GPC_depresion_en_cancer_de_mama.pdf</a> .	Focused on specific populations
175. Concurrent Treatment for Substance Use Disorder and Trauma-Related Comorbidities: 2021 Update. Available from: <a href="https://www.cadth.ca/concurrent-treatment-substance-use-disorder-and-trauma-related-comorbidities-2021-update">https://www.cadth.ca/concurrent-treatment-substance-use-disorder-and-trauma-related-comorbidities-2021-update</a> .	Focused on specific populations
176. US Preventive Services Task Force. Interventions to prevent perinatal depression. <i>JAMA</i> , Chicago, v. 321, n. 6, p. 580-587. DOI <a href="http://doi.org/10.1001/jama.2019.0007">http://doi.org/10.1001/jama.2019.0007</a> .	Focused on specific populations
177. Galician Health Technology Assessment Agency. Clinical Practice Guideline on the Management of Major Depression in Adults. Santiago de Compostela, Spain: Galician Health Technology Assessment Agency, 2008.	Were outdated
178. National Collaborating Centre for Mental Health (UK). Depression. The Treatment and Management of Depression in Adults. Leicester, UK: British Psychological Society, 2010.	Were outdated
179. Agency for Healthcare Research and Quality. Detecting Depression in Older Adults with Dementia. Ann Arbor, MI: University of Michigan Health System; [s.d].	Focused on specific populations
180. Adult Depression in Primary Care. Bloomington, MN: ICSI, 2013.	Were outdated
181. Galletly C, Castle D, Dark F, <i>et al</i> . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. <i>Aust N Z J Psychiatry</i> 2016, 50(5):410-72. DOI:10.1177/0004867416641195.	Subject matter

Reference of the excluded CPG	Reasons for exclusion
182. Malhi GS, Bassett D, Boyce P, <i>et al.</i> Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. <i>Aust N Z J Psychiatry</i> 2015, 49(12):1087-206. DOI:10.1177/0004867415617657.	Were outdated
183. Karyotaki E, Smit Y, Cuijpers P, <i>et al.</i> The Long-term Efficacy of Psychotherapy, Alone or in Combination with Antidepressants, in the Treatment of Adult Major Depression. <i>Good Clinical Practice (GCP)</i> . Brussels, Belgium: Belgian psychotherapy Health Care Knowledge Centre (KCE), 2014. Available from: <a href="#">pression_Report_0.pdf</a> .	Focused on psychotherapy
184. MINISTERIO DE SALUD. Guía Clínica: Para el tratamiento de la Depresión en personas mayores de 15 años: Actualización en Psicoterapia. Santiago: MINSAL, (2017). Todos los derechos reservados. Este material puede ser reproducido total o parcialmente para fines de diseminación y capacitación. Prohibida su venta. ISBN: (número de registro) 1ª Edición: Santiago, 2017. Available from: <a href="https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2017/07/GPC_depresion_psicoterapia.pdf">https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2017/07/GPC_depresion_psicoterapia.pdf</a> .	Focused on psychotherapy
185. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. <b>Vortioxetine for treating major depressive episodes</b> . London: NICE, 2015. Available from: <a href="https://www.nice.org.uk/guidance/ta367/resources/vortioxetine-for-treating-major-depressive-episodes-pdf-82602733813189#:~:text=Vortioxetine%20(Brintellix%2C%20Lundbeck)%20is,major%20depressive%20episodes'20in%20adults">https://www.nice.org.uk/guidance/ta367/resources/vortioxetine-for-treating-major-depressive-episodes-pdf-82602733813189#:~:text=Vortioxetine%20(Brintellix%2C%20Lundbeck)%20is,major%20depressive%20episodes'20in%20adults</a> '.	Specific drugs
186. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. <b>Agomelatine for the treatment of major depressive episodes(terminated appraisal)</b> . London: NICE, 2011. Available from: <a href="https://www.nice.org.uk/guidance/ta231/resources/agomelatine-for-the-treatment-of-major-depressive-episodes-terminated-appraisal-pdf-82600_365554629">https://www.nice.org.uk/guidance/ta231/resources/agomelatine-for-the-treatment-of-major-depressive-episodes-terminated-appraisal-pdf-82600_365554629</a> .	Specific drugs
187. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> . 2017 Apr 1, 74(4):399-405. DOI: 10.1001/jamapsychiatry.2017.0080. PMID: 28249076.	Specific drugs
188. Tran K, Argáez C. Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2020 Jan 30. PMID: 33074605.	Specific drugs
189. Esketamine for Treatment-Resistant Depression. Available from: <a href="https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/esketamine-for-treatment-resistant-depression">https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/esketamine-for-treatment-resistant-depression</a> ketamine for Treatment-Resistant Depression.	Specific drugs

<b>Reference of the excluded CPG</b>	<b>Reasons for exclusion</b>
190. Tran K, McGill SC, Horton J. Bupropion for Treatment-Resistant Depression [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2021 Apr. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK571945/">https://www.ncbi.nlm.nih.gov/books/NBK571945/</a> .	Specific drugs
191. Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines. Ottawa: CADTH; 2018 Feb. (CADTH rapid response report: summary of abstracts). Available from: <a href="https://www.cadth.ca/sites/default/files/pdf/htis/2018/RB1196%20Antidepressants%20with%20opioid%20use%20Final.pdf">https://www.cadth.ca/sites/default/files/pdf/htis/2018/RB1196%20Antidepressants%20with%20opioid%20use%20Final.pdf</a>	Was not a CPG